

Table 1. Time course of adverse events in the GARNET trial

Preferred term, n (%)	Overall N=515	500 mg Q3W				1000 mg Q6W			
		C1 N=515	C2 N=468	C3 N=421	C4 N=382	C5 N=322	C6 N=250	C7 N=214	C8 N=195
Any-grade TRAEs occurring in ≥10% of pts									
Fatigue	77 (15.0)	34 (6.6)	11 (2.4)	7 (1.7)	4 (1.0)	3 (0.9)	5 (2.0)	2 (0.9)	0
Diarrhea	66 (12.8)	27 (5.2)	15 (3.2)	9 (2.1)	4 (1.0)	2 (0.6)	3 (1.2)	3 (1.4)	0
Asthenia	59 (11.5)	27 (5.2)	12 (2.6)	7 (1.7)	6 (1.6)	2 (0.6)	2 (0.8)	1 (0.5)	1 (0.5)
Nausea	56 (10.9)	23 (4.5)	12 (2.6)	8 (1.9)	5 (1.3)	3 (0.9)	2 (0.8)	1 (0.5)	1 (0.5)
Grade ≥3 TRAEs occurring in ≥1% of pts									
Anemia	9 (1.7)	2 (0.4)	3 (0.6)	1 (0.2)	1 (0.3)	0	1 (0.4)	0	0
Fatigue	8 (1.6)	2 (0.4)	1 (0.2)	1 (0.2)	0	3 (0.9)	0	0	0
Lipase increased	7 (1.4)	0	2 (0.4)	2 (0.5)	0	1 (0.3)	0	0	0
Alanine aminotransferase increased	5 (1.0)	2 (0.4)	0	0	1 (0.3)	1 (0.3)	0	0	1 (0.5)
Diarrhea	5 (1.0)	0	1 (0.2)	2 (0.5)	1 (0.3)	0	1 (0.4)	0	0
Any-grade irTRAEs occurring in ≥2% of pts									
Hypothyroidism	34 (6.6)	0	2 (0.4)	3 (0.7)	13 (3.4)	2 (0.6)	5 (2.0)	5 (2.3)	3 (1.5)
Diarrhea	19 (3.7)	3 (0.6)	8 (1.7)	2 (0.5)	3 (0.8)	0	2 (0.8)	0	0
Alanine aminotransferase increased	11 (2.1)	4 (0.8)	0	0	3 (0.8)	2 (0.6)	1 (0.4)	0	1 (0.5)

C, cycle.